Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to ...